The Changing Landscape of Advanced Prostate Cancer Treatment: A Guidelines and Case-Based Discussion Webcast (2020)

As a direct result of the significant increase in multiple FDA-approved therapeutic agents for use in patients with advanced prostate cancer, clinicians are challenged with a multitude of treatment options and potential sequencing of these agents that, consequently, make clinical decision-making more complex. This activity will build upon the newly updated 2020 AUA Guidelines on Metastatic Hormone Sensitive Prostate Cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC). Topics will include the latest on Genetic Testing in Advanced Prostate Cancer and the Role of Immunotherapy and PARP Inhibitors.

Needs assessment findings show strong support for continued development of courses and educational materials specifically targeted at residents and fellows that cover the medical management of advanced prostate cancer. This activity may also be of interest to urologists and other health care providers who care for patients with prostate cancer.

This activity will cover the following topics:

  • Identification of High Risk Disease and Initial Management of Biochemical Recurrence
  • Imaging of Advanced Prostate Cancer
  • Management of mHSPC: A Case-based Discussion of Chemohormonal Therapy and the Evolving Role of Local Therapy in Oligometastatic Disease
  • M0 CRPC: Treatment Options and Goals of Therapy
  • Genetic Testing in Advanced Prostate Cancer
  • Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents in mHSPC and CRPC
  • Role of Immunotherapy and PARP Inhibitors
  • Radionuclide Therapy and Bone Health
  • Role of Chemotherapy and Treatment Sequencing

ACKNOWLEDGEMENTS

This educational activity is supported by independent educational grants from:

  • AbbVie
  • AstraZeneca
  • Bayer HealthCare Pharmaceuticals Inc.
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Merck

Target Audience

  • Urologist
  • Resident
  • Advanced Practice Provider (Nurse Practitioners & Physician Assistants)
  • Nurse

Learning Objectives

At the conclusion of this activity, participants will be able to:  

PRACTICE GAP #1 (DISEASE STATE)

  1. Describe the natural course of advanced prostate cancer from non-metastatic (M0) to metastatic hormone-sensitive disease (mHSPC), with progression to the development of castration-resistant disease (CRPC).
  2. Describe the treatment options and outcomes for patients with biochemical recurrence after failed local therapy.
  3. Identify available imaging and indications for use including next generation PET imaging in the assessment of men with biochemical recurrence after failed local therapy.
  4. Describe the treatment options and outcomes for newly diagnosed mHSPC.
  5. Explain the implications of CRPC on the management of both M0 and M1.
  6. Discuss the molecular mechanisms and characterization of CRPC.
  7. Discuss the incorporation of genetic testing (both germline and somatic testing) into the management of men with high risk, metastatic prostate cancer and CRPC.

PRACTICE GAP #2 (GUIDELINES)

  1. Discuss specific recommendations within the AUA Clinical Practice Guidelines.
  2. Define M0 CRPC and the treatment options.
  3. Discuss clinically meaningful endpoints in clinical trials of patients with MO CRPC.
  4. Describe gaps in the knowledge for treatment and sequencing of agents in the management of CRPC.
  5. Discuss challenges in incorporating AUA Guidelines and management of advanced mHSPC and CRPC into community practice.

PRACTICE GAP #3 (ANDROGEN AXIS)

  1. Identify approved androgen biosynthesis and receptor blockers for treatment of CRPC.
  2. Appraise the clinical use and efficacy of approved androgen-axis therapeutics for CRPC.
  3. Anticipate, manage and treat adverse events from therapeutic interventions directed at the androgen-axis used in the treatment of CRPC.
  4. Discuss new uses for androgen axis agents in M0 CRPC.

PRACTICE GAP #4 (CHEMOTHERAPY, IMMUNOTHERAPY, PARP INHIBITORS AND CO-MORBIDITY)

  1. Identify approved chemotherapeutics, immunotherapy and PARP Inhibitors for mCRPC.
  2. Describe indications and contraindications for chemotherapy, immunotherapy and PARP Inhibitors in patients with mCRPC.
  3. Identify co-morbid states and recognize their impact on treatment options for mCRPC.
  4. Identify germ-line and somatic mutations and implications for treatment in mCRPC.
  5. Discuss treatment sequencing.

PRACTICE GAP #5 (BONE HEALTH AND RADIONUCLIDE THERAPY)

  1. Integrate advances in bone health management into patient-specific care plans.
  2. Identify patients and prescribe radionuclide therapy in appropriate patients with symptomatic mCRPC.
  3. Discuss known adverse events associated with androgen biosynthesis inhibitors and radionuclide therapy.

PRACTICE GAP #6 (PAIN MANAGEMENT AND PALLIATIVE CARE)

  1. Assess and manage pain in patients with symptomatic mHSPC and mCRPC.
  2. Discuss the role of chemotherapy, performance status and pain management in patients with mCRPC.
Course summary
Available credit: 
  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Non-Physician Participation
Course opens: 
10/23/2020
Course expires: 
10/23/2021
Rating: 
0

The Changing Landscape of Advanced Prostate Cancer Treatment:
A Guidelines and Case-based Discussion Webinar

Presented Live on Wednesday, October 21, 2020 

SESSION I

 Identification of High Risk Disease and Initial Management of Biochemical Recurrence
Dr. Boorjian
 Imaging of Advanced Prostate Cancer
Dr. Stratton
 Management of mHSPC: A Case-based Discussion of Chemohormonal Therapy and the Evolving Role of Local Therapy in Oligometastatic Disease
Moderators: David F. Jarrard, MD & Dr. Lang
 M0 CRPC: Treatment Options and Goals of Therapy
Dr. Cookson
 Genetic Testing in Advanced Prostate Cancer
Dr. Gomella
 Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents in mHSPC and CRPC
Dr. Jarrard

SESSION II

 Role of Immunotherapy and PARP Inhibitors
Dr. Morgans
 Radionuclide Therapy and Bone Health
Dr. Boorjian

SESSION III

 Role of Chemotherapy and Treatment Sequencing
Dr. Lang

Education Council & COI Reviewer Disclosures

PDF icon Education Council & COI Reviewer Disclosures.pdf

 

AUA Office of Education Staff has nothing to disclose.

Course Director(s)

Michael Cookson, MD,MHA

has a financial relationship (Independent contractor) with Astellas Pharma, Inc.;.
has a financial relationship (Independent contractor) with Myovant Sciences;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Bayer Healthcare Pharmaceuticals;.
has a financial relationship (Independent contractor) with TesoRx Pharma LLC;.
has a financial relationship (Independent contractor) with Ferring Pharmaceuticals;.

David Jarrard, MD

has no relevant financial relationships to disclose at this time.
Faculty(s)

Stephen Boorjian, MD

has a financial relationship (Independent contractor) with ArTara;.
has a financial relationship (Independent contractor) with FerGene;.
has a financial relationship (Independent contractor) with Ferring;.

Leonard Gomella, MD

has a financial relationship (Independent contractor) with Merck Pharmaceuticals;.
has a financial relationship (Independent contractor) with Canadian Journal of Urology;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Strand laboratories;.
has a financial relationship (Independent contractor) with Wolters Kluwer;.
has a financial relationship (Independent contractor) with McGraw Hill;.
has a financial relationship (Independent contractor) with MDx Health;.
has a financial relationship (Independent contractor) with Merck Manual;.

Joshua Lang, MD, MS

has a financial relationship (Other Business Ownership) with Salus Discovery, LLC;.

Alicia Morgans, MD

has a financial relationship (Independent contractor) with Clovis;.
has a financial relationship (Independent contractor) with Sanofi;.
has a financial relationship (Independent contractor) with Pfizer;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Myovant;.
has a financial relationship (Independent contractor) with Astellas;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Independent contractor) with Genetech;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Astra Zeneca;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with BMS;.

Kelly Stratton, MD

has a financial relationship (Independent contractor) with Bayer ;.
has a financial relationship (Other) with Oakstone;.
has a financial relationship (Other) with Genentech;.
has a financial relationship (Independent contractor) with Integra Life Sciences Services, LLC (LUGPA);.
has a financial relationship (Other) with Astellas Pharma;.
has a financial relationship (Independent contractor) with Dendreon;.
has a financial relationship (Other) with Roche/Genentech;.
has a financial relationship (Other) with Ebix;.
has a financial relationship (Other) with Myovant Sciences;.

METHOD OF PARTICIPATION: 

Learners will participate in this online educational activity by taking the pretest, viewing the webcast and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 3 hours

Release Date: October, 2020
Expiration Date: October, 2021

ACCREDITATION: 

The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION: 

The American Urological Association designates this enduring material for a maximum of 3.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER LEARNERS: 

The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

EVIDENCE BASED CONTENT: 

It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA DISCLOSURE POLICY: 

All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST: 

All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group for identification of conflicts of interest. The AUA COI Review Work Group, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or AUA COI Review Work Group.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES: 

The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Non-Physician Participation
Please login or register to take this course.